Objectives: Clinical resistance to the currently recommended extended-spectrum cephalosporins (ESCs), the last remaining options for empirical antimicrobial monotherapy of gonorrhoea globally, has been reported. New antimicrobials are essential to avoid the emergence of untreatable gonorrhoea. We have investigated the in vitro activity of a novel dual bacterial topoisomerase inhibitor of the ATPase activities of GyrB and ParE (Vertex aminobenzimidazole VT12-008911), compared with antimicrobials currently or previously recommended for gonorrhoea treatment.
Introduction
Gonorrhoea is a global public health problem 1 and its causative agent Neisseria gonorrhoeae has developed resistance to all previously introduced and currently recommended antimicrobials for the treatment of this infection. 2 -8 During the last decade, a steady increase in the MIC values of the extended-spectrum cephalosporins (ESCs) has been observed worldwide, which has been clinically reflected in multiple reports of treatment failures, particularly with cefixime 9 -16 and in some instances with ceftriaxone. 17 -21 Furthermore, N. gonorrhoeae strains with high-level resistance to cefixime, ceftriaxone and most other available antimicrobials [i.e. extensively drug resistant (XDR)] 22 have been isolated recently. 15, 20, 23 Ceftriaxone is the last remaining option for antimicrobial monotherapy of gonorrhoea. This has urged the health protection organizations worldwide to act against the threat of gonorrhoea becoming an untreatable infection. 24 -27 Furthermore, dual antimicrobial therapy with ceftriaxone and either azithromycin or doxycycline is now recommended in the USA and Europe. 28, 29 However, the evidence that the combinations are synergistic or even additive in vivo for treatment of gonorrhoea are mainly theoretical and N. gonorrhoeae strains with resistance to both of the antimicrobials included in the combination have already been isolated. 3, 15, 20, 23 In addition, dual antimicrobial therapy may not be feasible or affordable in all clinical settings globally.
Consequently, alternatives to the currently recommended antimicrobials are urgently needed and candidates have been sought among some of the existing antimicrobials. Gentamicin has been used in the syndromic management of urethritis (usually combined with doxycycline) in Malawi for 20 years. 30, 31 The in vitro susceptibility of N. gonorrhoeae to gentamicin in Europe also appears high 32 and this antimicrobial has been suggested for use more widely in the treatment of gonorrhoea, particularly as one of the components of a dual treatment regimen. 3, 28, 31, 33, 34 In vitro results have suggested that ertapenem might be an effective treatment option, particularly in cases of ESC-resistant gonorrhoea or in dual antimicrobial therapy. 35 One of the few novel antimicrobials currently in the pre-clinical or clinical stage of development is the fluoroketolide solithromycin, which has been shown to have high activity in vitro against gonococcal isolates and has also been shown to be effective in a small Phase 2 clinical trial. 36, 37 Nevertheless, this antimicrobial might not be ideal for first-line antimicrobial monotherapy of gonorrhoea, but may be more suitable for ESC-resistant cases and as a component of a dual antimicrobial regimen. 3 Bacterial DNA gyrase and topoisomerase IV are highly conserved type II topoisomerases that are essential for DNA replication. They act by breaking and rejoining double-stranded DNA in a reaction that is coupled with ATP hydrolysis. Both enzymes are highly homologous functional A 2 B 2 heterotetramers comprising the GyrA and GyrB subunits (DNA gyrase) and the ParC and ParE subunits (topoisomerase IV). The essential function of DNA gyrase is to introduce negative supercoils into DNA during replication, while topoisomerase IV is involved in the separation of the two catenated daughter chromosomes after replication is completed. While GyrA/ParC (the catalytic subunits) are well known and served as targets for antimicrobial agents (e.g. fluoroquinolones such as ciprofloxacin), inhibitors of GyrB/ParE (the ATPase subunits) have been less exploited as targets and with limited success (e.g. coumarins). 38 -40 However, a novel aminobenzimidazole class of antimicrobials has recently been developed using structure-guided design, modelling and structure -activity relationship principles. Those antimicrobials are low molecular weight, potent dual inhibitors of the bacterial DNA gyrase and topoisomerase IV enzymes that target the GyrB and ParE subunits, which translates into a potent antimicrobial activity against both Gram-positive and some Gram-negative bacterial species. 40 -43 The antimicrobial activity of the aminobenzimidazole class against clinical N. gonorrhoeae isolates has not been previously published.
The aim of this study was to investigate the in vitro antimicrobial activity of the novel dual bacterial topoisomerase inhibitor VT12-008911, which blocks the ATPase activities of GyrB and ParE, against a large collection of international reference strains and clinical isolates, including the described XDR isolates 15, 20, 23 and additional ESC-resistant, ciprofloxacin-resistant and multidrugresistant (MDR) 22 isolates of N. gonorrhoeae. We also investigated the bactericidal activity of VT12-008911 using time -kill curve analysis and determined the frequency of resistance mutations following growth in the presence of this antimicrobial.
Materials and methods
The work was performed at the WHO Collaborating Centre for Gonorrhoea and Other STIs, National Reference Laboratory for Pathogenic Neisseria, Department of Laboratory Medicine, Microbiology, Ö rebro University Hospital, Ö rebro, Sweden.
N. gonorrhoeae isolates
A large collection of clinical N. gonorrhoeae isolates and international reference strains (n ¼ 248) was tested. The collection included consecutive clinical isolates from Sweden cultured in 2012 (n ¼ 100), clinical isolates obtained from 2000 to 2011 that were selected based on their resistance phenotype (n¼120) and international reference strains (n¼28). Thus, the panel represented a geographically (mainly global representativeness), temporally and genetically diverse selection of isolates. The collection included all three currently described N. gonorrhoeae XDR strains with high-level resistance to ESCs, 15, 20, 23 strains implicated in treatment failures with cefixime and ceftriaxone 11, 13, 15, 17, 18, 20 and as numerous ciprofloxacin-resistant and MDR isolates. Finally, the international reference strains included the WHO A-E, WHO I, WHO J, MS-11, FA1090 and the eight WHO 2008 N. gonorrhoeae reference strains. 44 Prior to testing, all N. gonorrhoeae isolates were cultured on Difco GC Medium Base agar (BD Diagnostics, Sparks, MD, USA) supplemented with 1% IsoVitalex (BD Diagnostics).
Determination of the MIC of VT12-008911 using the agar dilution method
The VT12-008911 compound was provided by Vertex Pharmaceuticals Incorporated (Boston, MA, USA). The MIC (mg/L) of VT12-008911 was determined using the reference agar dilution technique, in accordance with the recommendations of the CLSI (formerly NCCLS). 45 Briefly, agar plates with Difco GC Medium Base agar (BD Diagnostics) supplemented with 1% IsoVitalex (BD Diagnostics) were used with concentrations of VT12-008911 ranging from 0.002 to 16 mg/L and without VT12-008911 for growth control (two plates in each testing). Antimicrobial powder was dissolved as instructed by the manufacturer in sterile DMSO at a concentration of 10 mg/mL as a stock solution and stored frozen until used. Two working dilutions [1: 40 and/or 1: 400 (for low MICs)] were prepared using DMSO on the day of testing and the final concentration of DMSO in the agar plates did not exceed 0.8% (v/v). Stock solutions and agar plates were kept in the dark, except during preparation for testing. Bacterial suspensions with a turbidity equivalent to that of a 0.5 McFarland standard were prepared from 18-20 h cultures of N. gonorrhoeae. A standardized inoculum of 10 4 cfu/spot was applied using a Multipointelite inoculator (MAST Group Ltd, Bootle, UK) and the inoculated agar plates were subsequently incubated at 368C in 5% CO 2 for 24 h. The WHO B (MIC VT12-008911 ¼ 0.004 mg/L) and WHO C (MIC VT12-008911 ¼ 0.125 mg/L) N. gonorrhoeae reference strains were used as quality controls for the MIC determinations at both low and high MIC ranges of VT12-008911. Two experienced technicians read the results of all agar plates. After reading, all spots with ambiguous growth were examined with an oxidase reaction test and reaction within 5-10 s was considered to indicate true growth.
Determination of MICs of additional antimicrobials using Etest
The MICs (mg/L) of ciprofloxacin, tetracycline, azithromycin, ampicillin, cefixime, ceftriaxone and spectinomycin were determined by the Etest Activity of VT12-008911 against N. gonorrhoeae 1867 JAC method (AB, bioMé rieux, Solna, Sweden) using the same medium and incubation parameters as above, in accordance with the manufacturer's instructions. The results were interpreted in accordance with EUCAST clinical breakpoints (bacteria v 3.1; www.eucast.org/clinical_breakpoints). Only whole MIC dilutions are reported in the present article. The 2008 WHO N. gonorrhoeae reference strains 44 were used for quality control for all the Etests.
Time -kill curve analysis and minimum bactericidal concentration (MBC) of VT12-008911 for three N. gonorrhoeae reference strains VT12-008911 was investigated for bactericidal activity against three reference strains of N. gonorrhoeae (ATCC 49226, 19424 and 31426) using both a standard broth time -kill curve analysis and an MBC assay. For comparison, the fluoroquinolone ciprofloxacin and tetracycline were also tested. Briefly, the MIC values of all three antimicrobials were determined by the CLSI reference agar dilution technique. 45 For the time-kill curve analysis, the MICs of the three antimicrobials were also determined by a broth microdilution method 46 using Fastidious Broth (Remel, Lenexa, KS, USA). The MICs of VT12-008911 and ciprofloxacin for the three reference strains were similar using the agar dilution and broth microdilution methods and ranged from 0.03 to 0.12 mg/L and from ≤0.004 to 0.008 mg/L, respectively. Time -kill curve analysis was performed in Fastidious Broth (Remel) for all three antimicrobials, in accordance with Moody and Knapp 47 and recommendations (M21-A 48 and M26-A 49 ) of the CLSI (www.clsi.org). All testing was performed in duplicate at 2×, 4× and 8× MIC of the three antimicrobials and a growth control without any antimicrobial was included. cfu counts were performed at intervals during 24 h, i.e. at T 0 , T 1 , T 2 , T 4 , T 8 and T 24 . For all strains, the T 0 counts were 5 -6×10 5 cfu/mL and the growth control, lacking antimicrobial, showed a steady increase up to 8 -9×10 8 cfu/mL at 24 h. MBC values were determined by culturing the broth from the MIC microdilution tray endpoint well of each isolate and from those log 2 dilutions at and above the MIC for each isolate onto GC agar plates. Quantitative cfu counts were performed on the starting inoculum at the time the MIC test was performed. The lowest concentration of antimicrobial agent that killed ≥99.9% of the initial test inoculum was defined as the MBC endpoint, as previously described. 50 Resistance mutation frequencies and single-step mutational analysis of VT12-008911 for three N. gonorrhoeae reference strains
The resistance mutation frequency was determined for three reference strains of N. gonorrhoeae (ATCC 49226, 19424 and 31426) inoculated onto GC medium containing VT12-008911 at 2×, 4× and 8× MIC of VT12-008911 for the different strains. Briefly, fresh gonococcal colonies from a GC agar plate were suspended in Fastidious Broth (Remel) to a turbidity equivalent to that of a 4 McFarland standard ( 1.2×10 9 cfu/mL). From this gonococcal suspension, 0.1 and 1 mL was plated on VT12-008911-containing agar plates. Serial dilutions of the gonococcal suspension were plated on antimicrobial-free GC agar plates to quantify the cfu/mL for each strain. All tests were performed in duplicate. For comparison, agar plates containing the fluoroquinolone ciprofloxacin were also used, i.e. containing 2×, 4× and 8× MIC of ciprofloxacin and following an identical protocol to the one used for VT12-008911. Resistant mutants that arose on the VT12-008911-containing selection agar plates were evaluated for increases in the MIC, conferred by single-step mutations, compared with the parent strain, using a broth microdilution method 46 utilizing Fastidious Broth (Remel).
Results
In vitro activity of VT12-008911 against N. gonorrhoeae isolates (n 5 248)
The susceptibility results of the novel aminobenzimidazole compound VT12-008911 and antimicrobials currently or previously recommended for a large collection of clinical isolates of N. gonorrhoeae (n ¼ 220) and international reference strains (n¼ 28) are summarized in Table 1 .
The MIC 50 , MIC 90 and MIC range of VT12-008911 were 0.064, 0.125 and ≤0.002 -0.25 mg/L, respectively. Only 14 isolates (5.6%) had the highest MIC value observed, i.e. MIC of VT12-008911 of 0.25 mg/L (Figure 1a) .
In vitro activity of VT12-008911 compared with the previously recommended fluoroquinolone ciprofloxacin
Compared with VT12-008911, the MIC 50 , MIC 90 and MIC range of ciprofloxacin were substantially higher, i.e. 4, .32 and ≤0.002 to .32 mg/L, respectively (Table 1) . Accordingly, the MIC 50 and MIC 90 of ciprofloxacin were 64-and .256-fold higher, respectively. In total, 170 (69%) of the isolates showed resistance to ciprofloxacin (34% had an MIC .32 mg/L); however, only 81 (33%) of all isolates had a VT12-008911 MIC . Jeverica et al.
In vitro activity of VT12-008911 compared with currently (ESCs) and previously recommended antimicrobials for gonorrhoea treatment
In total, 11.7% and 2.8% of the isolates were resistant to the currently recommended ESCs cefixime and ceftriaxone, respectively (Table 1) . Among the isolates with resistance to cefixime (n¼ 29) and ceftriaxone (n ¼ 7), the MIC 50 , MIC 90 and MIC range of VT12-008911 were 0.064, 0.125 and ≤0.032-0.25 mg/L, respectively, i.e. the isolates were spread in the presumed wild-type MIC distribution of VT12-008911. Furthermore, all three N. gonorrhoeae XDR strains, 15, 20, 23 Large percentages of the isolates tested in this study were resistant also to other antimicrobials previously recommended for gonorrhoea treatment (Table 1) , including tetracycline (67.3%), azithromycin (41.1%), ampicillin (18.5%) and spectinomycin (2.0%). All isolates with low-or high-level resistance to any of those antimicrobials were spread in the presumed wildtype MIC distribution of VT12-008911.
No obvious cross-resistance between the novel dual bacterial topoisomerase inhibitor VT12-008911 and any of the tested antimicrobials was identified.
Time -kill curve analysis and MBC of VT12-008911 for three N. gonorrhoeae reference strains
MBCs indicated that VT12-008911 had a bactericidal activity against N. gonorrhoeae at or very close to the MIC [1× MIC for ATCC 49226 (0.12 mg/L) and ATCC 19424 (0.06 mg/L) and 2× MIC for ATCC 31426 (0.12 mg/L)]. The time -kill curve analyses showed that VT12-008911 had slower bactericidal activity compared with ciprofloxacin, but demonstrated a more rapid bactericidal effect than tetracycline, which might be expected as tetracycline is a bacteriostatic antimicrobial agent. At the 8 h timepoint, VT12-008911 (≥2× MIC) achieved the bactericidal threshold (3 log reduction in viable cells) for two of the strains (ATCC 19424 and 31426) and reduced the viable counts of the third strain (ATCC 49226) by 1.5 -2 log. At the 24 h timepoint, VT12-008911 was bactericidal against all three strains, reducing the number of viable cells below the lower limit of detection, even at 2× MIC. The bactericidal activity of VT12-008911 was largely time dependent, but not concentration dependent. In contrast, ciprofloxacin displays concentration-dependent bactericidal activity against N. gonorrhoeae. Overall, these results indicate that VT12-008911 has potent, time-dependent bactericidal activity against N. gonorrhoeae.
Resistance mutation frequencies and single-step mutational analysis of VT12-008911 for three N. gonorrhoeae reference strains
The resistance mutation frequency was determined for three reference strains of N. gonorrhoeae (ATCC 49226, 19424 and 31426) inoculated onto GC medium containing VT12-008911 at 2×, 4× and 8× MIC of the compound. At 2× MIC of VT12-008911, resistant mutants arose at a frequency between 1×10 27 and 2×10
28
(per cfu). At 4× MIC of VT12-008911, the mutation frequency was below the limit of detection for two strains (,1.2×10 29 and ,4×10 29 for ATCC 49226 and 31426, respectively) and 1×10 28 for the third strain (ATCC 19424). At 8× MIC of VT12-008911, the mutational frequency was below the limit of detection for all three strains (,1.2×10 29 to ,4×10 29 ). These low resistance mutation frequency values are consistent with the predicted dual targeting mechanism of VT12-008911. In general, mutants that arose on the compound-containing selection agar plates had relatively small increases in the MIC of VT12-008911. Many of the tested mutants had no increase in the MIC or a negligible 2× increase in the MIC of VT12-008911. Nevertheless, mutants with a 4× increase in the MIC were also selected from strains ATCC 19424 and ATCC 31426 and a single isolate with an 8× increase in the MIC (derived from ATCC 19424) was observed. This was in contrast to ciprofloxacin, for which mutants with a ≥30× increase in the MIC were readily selected at 2× the parental MIC. Overall, the resistance frequency of N. gonorrhoeae strains selected by inoculation onto GC medium containing VT12-008911 was low and the selected single-step mutations resulted in a relatively low level of resistance (no selected mutant had an MIC of VT12-008911 .0.25 mg/L).
Discussion
We report the first evaluation of the antimicrobial activity of the novel aminobenzimidazole compound VT12-008911, a dual inhibitor of the ATPase activities of bacterial DNA gyrase (GyrB) and topoisomerase IV (ParE) enzymes, against a large and diverse collection of N. gonorrhoeae clinical isolates and international reference strains, relative to the activities of other antimicrobial agents currently or previously recommended for the treatment of gonorrhoea. The collection contained geographically, temporally and genetically diverse N. gonorrhoeae isolates and included all three recently described XDR strains with high-level resistance to ESCs, 15, 20, 23 additional isolates with clinical ESC resistance and a high number of isolates with ciprofloxacin resistance and different types of multidrug resistance.
VT12-008911 was highly active against all tested gonococcal isolates and had a narrow MIC range, a low MIC 50 and a low MIC 90 (≤0.002 -0.25, 0.064 and 0.125 mg/L, respectively). The MIC values of VT12-008911 were substantially lower than those of the previously recommended fluoroquinolone ciprofloxacin, which also targets DNA gyrase (GyrA) and DNA topoisomerase IV (ParC), and appeared to mainly represent an MIC distribution including only wild-type isolates, i.e. lacking resistance mechanisms for VT12-008911. Furthermore, there was no substantial difference between the MIC range, MIC 50 and MIC 90 values of VT12-008911 for the ciprofloxacin-resistant isolates (≤0.002 -0.25, 0.064 and 0.25 mg/L, respectively) and the ciprofloxacinsusceptible isolates (0.004 -0.25, 0.064 and 0.125 mg/L, respectively) ( Figure 1 ). In comparison with all antimicrobial agents tested in the present study (ceftriaxone, cefixime, azithromycin, ciprofloxacin, ampicillin, tetracycline and spectinomycin), which represent all major classes of antimicrobials currently and previously used to treat gonorrhoea, the in vitro activity of VT12-008911 appeared superior and no MIC value .0.25 mg/L was observed. Time -kill curve analysis and MBC assays of VT12-008911, for three N. gonorrhoeae reference strains, indicated that VT12-008911 has bactericidal activity against N. gonorrhoeae at or very close to the MIC. The bactericidal activity against N. gonorrhoeae was shown to be largely time dependent, but not concentration dependent, as is the case for ciprofloxacin. Overall, while the killing kinetics of VT12-008911 was less rapid compared with ciprofloxacin, the results indicated that after 24 h the VT12-008911 was bactericidal against all three tested reference strains and that VT12-008911 has a potent, timedependent bactericidal activity against N. gonorrhoeae.
VT12-008911 might be an effective option for future treatment of gonorrhoea. The full potential of this compound against gonorrhoea as well as other bacterial sexually transmitted infections such as Chlamydia trachomatis infections and Mycoplasma genitalium infections will only be understood after an appropriately designed clinical study. However, to reduce the development of resistance and thus sustain potent activity against N. gonorrhoeae, it might be advisable to restrict the use of an efficacious antimicrobial to the treatment of gonorrhoea.
Previous studies with two earlier developed aminobenzimidazole agents showed that those compounds had excellent antimicrobial activity against many Gram-positive bacteria as well as activity against some Gram-negative respiratory pathogens, i.e. Haemophilus influenzae and Moraxella catarrhalis. 42 Those earlier aminobenzimidazole agents were bactericidal and only low levels of resistant mutants were selected at subinhibitory concentration of the compounds. 43 In the present study, the resistance mutation frequency was determined for three reference strains of N. gonorrhoeae (ATCC 49226, 19424 and 31426) inoculated onto GC medium containing VT12-008911 at 2×, 4× and 8× MIC of the compound. Those results showed that the resistance mutation frequency of N. gonorrhoeae strains selected by inoculation onto GC medium containing VT12-008911 is low and the single-step mutations selected result in a relatively low increase in the MIC of VT12-008911 (no selected mutant had an MIC of VT12-008911 .0.25 mg/L). This was in contrast to ciprofloxacin, for which mutants with a ≥30× increase in the MIC were readily selected at 2× the parental MIC. The low resistance mutation frequency values of VT12-008911 are consistent with the lower mutation frequency expected from the dual targeting mechanism. Thus, the dual inhibition of GyrB and ParE of VT12-008911 is expected to minimize the frequency of emerging resistance mutations and, accordingly, maximize the effectiveness as well as the longevity of those antibiotics in treatment.
In conclusion, in order to avoid the emergence and spread of untreatable gonorrhoea, new treatment strategies, particularly the development of novel antimicrobial agents for the treatment of gonorrhoea, are essential. The present study shows that VT12-008911, a novel dual inhibitor of DNA gyrase and topoisomerase IV from the recently described aminobenzimidazole class of antimicrobial agents, has superior in vitro activity compared with the fluoroquinolone ciprofloxacin and other currently and previously recommended antimicrobials for the treatment of gonorrhoea against a large and diverse collection of N. gonorrhoeae isolates with various high-level antimicrobial resistance and multidrug resistance. These in vitro results indicate that VT12-008911 might be a promising novel candidate for future treatment of gonorrhoea. However, it will be important to perform well-designed pharmacokinetic/pharmacodynamic studies, toxicity and safety analysis in animal models, additional in vitro studies addressing the selection and mechanisms of VT12-008911 resistance in N. gonorrhoeae and, finally, in vivo randomized clinical trials in humans (measuring parameters such as efficacy, tolerability, toxicity and cost).
